Test Hypotheses Against Linked Evidence

 BGPT Odds of True

The hypothesis asserts BMBL282 hydrolyzes meropenem at a rate comparable to imipenem at 300 nm. No such direct assay exists in the supplied evidence; the paper's explicit falsification criterion identifies this exact missing test. Indirect signals (indifferent FICI 2, 2-fold vs 8-fold MIC shift) predict weak/no meropenem turnover, so likelihood of comparable rates is conservatively low.

 Hypothesis Novelty

The hypothesis is a targeted gap-analysis of one recently published enzyme's substrate spectrum rather than a new mechanistic concept; novelty rests mainly on the fact the critical assay was never performed.

 Quick Analysis Plan Copied

 Long Analysis Plan

Answer: the direct test has not been done, so the hypothesis cannot be confirmed or refuted from existing data. The BMBL282 paper reports Michaelis-Menten kinetics only for imipenem (Vmax 7.411×10⁻⁹ mol/s, Km 0.50 mM, kcat 2.52 s⁻¹, kcat/Km 5.04×10³ M⁻¹s⁻¹) monitored at 300 nm BMBL282 imipenem-only kinetic characterization. Critically, the paper's own falsification criterion explicitly names 'direct hydrolysis assay of meropenem by BMBL282 under the conditions used for imipenem' as the missing decisive test — meaning the authors themselves acknowledge the spectrophotometric comparison is unperformed.

Indirect evidence argues against comparable rates. Checkerboard assays give an indifferent meropenem FICI of 2 (both organisms) versus strongly antagonistic imipenem FICI of 16.08 and 8.01 FICI contrast imipenem vs meropenem. However, supplementary Fig. S7 shows meropenem MIC against C. oceanisediminis rises from <0.024 to 0.048 µg/mL with BMBL282 — an 8-fold smaller shift than imipenem's (<0.024 → 0.195 µg/mL). This small shift is ambiguous: it may reflect weak but real hydrolysis that FICI thresholds at high inoculum mask, or a non-catalytic interaction.

What comparable-rate meropenem hydrolysis would mean. If the 300 nm assay showed kcat/Km within ~10-fold of imipenem's, the 'imipenem-exclusive' framing would collapse into 'carbapenem-biased' — with implications for the paper's B3b subclass assignment (resting on sequence models and docking, not crystallography) and its in vivo survival data, which only tested imipenem. The imipenem-exclusive claim currently rests on negative indirect assays (FICI, disc diffusion, no AHL degradation) that are structurally insensitive to slow turnover Scope and blindspots of selectivity claim. A caveat: the authors' data do not preclude the alternative that meropenem is genuinely a poor substrate — the 2-fold MIC shift is small and could reflect real but marginal catalysis. Resolving this requires the exact missing experiment: meropenem 0.05–0.8 mM with Zn²⁺-loaded BMBL282 in 50 mM MOPS, monitored at 300 nm with heat-killed and EDTA controls, ideally confirmed by LC-MS product mapping given meropenem's overlapping absorbance at 300 nm.

Confidence note: High confidence that the direct assay is absent; moderate confidence that indirect signals predict weak meropenem turnover. The single-isolate, no-crystal-structure scope of the source paper limits generalization.